GENETIC TECHNOLOGIES LIMITED — AGM Information 2022

Nov 27, 2022

==> picture [216 x 115] intentionally omitted <==

Annual General Meeting November 28, 2022 Authorised by the Board of Directors of Genetic Technologies Limited

==> picture [245 x 540] intentionally omitted <==

ASX: GTG NASDAQ: GENE

==> picture [60 x 32] intentionally omitted <==

Agenda

• Chairman’s address – Mr Peter Rubinstein

• Business of the Meeting

• 2022 Annual Report and auditors’ report

• Resolutions

  1. Remuneration report

  2. Re-elect Mr Nick Burrows

  3. Increased placement capacity

  4. Amendment to the Constitution

• CEO address – Mr Simon Morriss

• Q&A

==> picture [297 x 372] intentionally omitted <==

Questions

To ask a written question, select the “Q&A’ icon and select the topic your question relates to

Type the question into the chat box at the bottom of the screen and press “Send”

Your question will be sent immediately for review Received

==> picture [288 x 260] intentionally omitted <==

==> picture [60 x 32] intentionally omitted <==

To ask a verbal question follow the instructions below the broadcast window.

.

Voting Instructions

When the poll is open, select the “Vote” icon and voting options will appear on your screen

To vote simply select the direction in which you would like to cast your vote. A tick will appear to confirm receipt of your vote

For Against Abstain

To change or cancel your vote, select “Click here to change your vote” and select a different option to override. You can change your vote any time before the poll is closed

==> picture [65 x 79] intentionally omitted <==

==> picture [263 x 253] intentionally omitted <==

==> picture [60 x 32] intentionally omitted <==

==> picture [60 x 32] intentionally omitted <==

Chairman's Address Mr. Peter Rubinstein

==> picture [60 x 32] intentionally omitted <==

Items of business

First item of business: to receive and consider the financial statements and reports for the year ended 30 June 2022

==> picture [60 x 32] intentionally omitted <==

Resolution 1: Adoption of the Remuneration Report

“That for the purpose of Section 250R(2) of the Corporations Act and all other purposes the Remuneration Report as set out in the Directors’ report for the Company for the year ended 30 June 2022 be adopted.”

==> picture [60 x 32] intentionally omitted <==

Resolution 1: Adoption of the Remuneration Report

• Proxy Voting:

Vote type Voted % For 541,123,404 83.3% Against 101,153,924 15.6% Open-Usable 7,467,502 1.1% Abstain 85,254,478

==> picture [60 x 32] intentionally omitted <==

Resolution 2: Re-Election of Mr Nick Burrows

“To elect Mr Nick Burrows who retires by rotation in accordance with clause 20.3 of the Company’s Constitution and being eligible offers himself for re-election as a Director.”

==> picture [60 x 32] intentionally omitted <==

Resolution 2: Re-Election of Mr Nick Burrows

• Proxy Voting:

Vote type	Voted	%
For	739,948,815	86.7%
Against	105,946,465	12.4%
Open-Usable	7,977,502	0.9%
Abstain	83,645,835

==> picture [60 x 32] intentionally omitted <==

Resolution 3: Approval of increased placement capacity

“That pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the increase in capacity of the Company to issue of Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and conditions in the Explanatory Statement accompanying this Notice of Meeting.”

Resolution 3: Approval of increased placement capacity • Proxy Voting: Vote type Voted % For 783,009,659 83.8% Against 142,988,184 15.3% Open-Usable 7,967,502 0.9% Abstain 3,553,272

==> picture [60 x 32] intentionally omitted <==

==> picture [60 x 32] intentionally omitted <==

Resolution 4: Amendment to the Constitution

“That for the of section of the purposes 136(2) Corporations Act, the existing constitution of the Company be amended as detailed in the Explanatory Memorandum, effective at the close of this meeting.”

Resolution 4: Amendment to the Constitution

==> picture [60 x 32] intentionally omitted <==

• Proxy Voting:

Vote type Voted % For 696,223,379 83.8% Against 126,326,114 15.2% Open-Usable 8,074,645 1.0% Abstain 106,894,479

==> picture [60 x 32] intentionally omitted <==

Chief Executive Officer Address Mr. Simon Morriss The Future: Unlocking personalised preventative medicine

World leading portfolio

Most comprehensive guideline driven portfolio for human and animal health.

• Patented GeneType Multi Risk Test

• Non-Invasive Prenatal Testing (NIPT)

• Carrier screen testing

• Pharmacogenomics

• Oncogenetic diseases

• Pet care

Revenues anchored by our 3 brands to seize a multi Billion-dollar opportunity.

16

==> picture [456 x 540] intentionally omitted <==

----- Start of picture text -----

* Patents granted are specific to the GeneType portfolio of products
----- End of picture text -----

==> picture [60 x 32] intentionally omitted <==

Patented* Genetype tests Integrate polygenic risk and clinical risks for critical medical conditions

Genetype tests integrate individual’s familial, clinical and genetic information to actionable clinical insights.

A non-invasive saliva based test combines genetic and clinical risk models with cutting-edge research. We’re leading a personalised healthcare revolution.

Our medical practitioners, scientists and technicians have developed the next generation of integrated predictive genetic testing and assessment tools – empowering physicians and patients to proactively manage health.

• ✓ 10 Patent families covering the GeneType products ✓ 4 Patents granted in the US

• ✓ 2 Patents granted in China

• ✓ 9 Patents pending Worldwide

17

Global Overview

==> picture [536 x 271] intentionally omitted <==

40

57

25

Countries

Employees Countries Patents globally Granted (9 Pending Worldwide) 14 51 12 Test Tests Partner Categories Laboratories

• Patents granted are specific to the GeneType portfolio of products

18

==> picture [60 x 32] intentionally omitted <==

Delivering Revenue and Growth – Q1 FY23

==> picture [308 x 227] intentionally omitted <==

----- Start of picture text -----

Cash Receipts (A$'000)
$6,789
145%
Growth
on LY
half-year ending December
31, 2021
$2,060
$89 $850
Full Year FY21 Full Year FY22 Q1 FY22 Q1 FY23
----- End of picture text -----

• CASH BALANCE A$7.9m* GROSS MARGIN 44%

• • Clinical utility demonstrated by the peer review publication of Genetype for Breast Cancer in the Journal of Precision Medicine

==> picture [144 x 174] intentionally omitted <==

----- Start of picture text -----

Q1 CASH RECEIPTS
A$2.06m
GROSS MARGIN
A$0.9m
----- End of picture text -----

Strategic & Operational Highlights:

• Cash receipts from customers A$2.06m with +145% on last year;

• Revenue A$1.93 million for the quarter, up 375% from (Q1 FY22)

• GeneType Risk Test outperforms traditional risk assessments for breast cancer in identifying risk by up to 9 times

• 5 consecutive qtrs. of growth on prior year

• GeneType Multi-Risk Test is implemented in 64 clinics building our geneType hub strategy

• Material progress in USA with Alva10 and large payer engagement

• Promoting to over 10,000 General practitioners (GPs) across Australia by leveraging Breast Cancer Awareness Month

• New USA business manager is making great progress with concierge medicine groups and independent doctor network

19

*Sept ’22 quarter end cash and cash equivalents of A$8.0 million as announced on ASX 25 October 2022 # All revenues for the period ‘21 & ‘22 are 'out of pocket' our strategy for reimbursement should become effective in 2023 FY

==> picture [60 x 32] intentionally omitted <==

Execute the B2B commercialisation of the geneType multi-risk test

Our FOCUS

Core ‘4’

Commercialisation of the geneType suite of multi-risk tests Commercialisation of the geneType suite of multi-risk tests Demonstrate clinical validity & clinical utility of geneType tests

EasyDNA & Affinity DNA Revenue Growth: Tests, Channels. & Markets

Innovation: Next Generation of capability – Starting with Epigenetics

==> picture [100 x 55] intentionally omitted <==

20

==> picture [60 x 32] intentionally omitted <==

Our Innovation – Multi-Risk Test

GeneType can identify patients ’at risk’ before onset and aid in the early detection and treatment.

GeneType Risk assessment test for breast cancer has demonstrated improved early stage detection by 18% and saving approx. US$1.4B per annum[4 ] for the US payer

Oncology

Diseases Areas

Cardiovascular

GeneType Multitest covers >70% of mortality & morbidity

Atrial Fibrillation

Breast Cancer

[insert revenue structuColorectal Cancer Co r one a ry Artery nd agreement Prostate Cancer types]Disease Melanoma Product list Pancreatic Cancer Metabolic Ovarian Cancer

Type 2 Diabetes

Phase 1 Launch[2] Phase 2 Launch[3]

Guideline driven, Actionable results

1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek

2. Commercial availability expected Q1 CY2022

3. Commercial availability upon regulatory approval 4. Budget Impact Model prepared by Alva10

21

GeneType Identifies up to 9 Times More Cancer Risk Patients Compared to Existing SoC Models[1]

==> picture [79 x 44] intentionally omitted <==

==> picture [290 x 350] intentionally omitted <==

==> picture [32 x 40] intentionally omitted <==

==> picture [286 x 351] intentionally omitted <==

==> picture [31 x 40] intentionally omitted <==

==> picture [186 x 350] intentionally omitted <==

The paper, titled “Integrating Personalised Medicine into Preventative Care through Risk Stratification” Published in the Journal of Precision Medicine 1 https://www.thejournalofprecisionmedicine.com/wp-content/uploads/integrating-personalized-medicine-preventive-care.pdf

==> picture [60 x 32] intentionally omitted <==

Pathways to Market Executing a multi-brand strategy

Medical & Payer Business to Business (B2B)

==> picture [258 x 151] intentionally omitted <==

==> picture [55 x 32] intentionally omitted <==

Oncology – GTG[insert revenue structure Cardiovascular Prenatal NIPT and agreement types] Carrier testingProduct list Clinical & Molecular Metabolic

Consumer initiated testing (CIT) with medical supervision

==> picture [259 x 151] intentionally omitted <==

==> picture [59 x 32] intentionally omitted <==

Expanded Carrier testing & NIPT [insert revenue structure Oncology – MultiTest Cardiovascular – MultiTestand agreement types] Metabolic – MultiTestProduct list COVID Rick Test Pharmacogenomics

Direct to Consumer Testing (DTC)

with no medical supervision

==> picture [259 x 151] intentionally omitted <==

Ancestryand agreement types]Animal Paternity Product listDrug testing Health & Wellbeing Relationship Pharmacogenetics DNA Storage

23

==> picture [60 x 32] intentionally omitted <==

Pathways to Market – highest priority

Revenue

Drivers

Partners

Medical & Payer Business to Business (B2B)

Health Economic modeling completed by ALVA10*

• Certifying reimbursable testing platform: [insert revenue BRCA test & LYNCH Syndrome teststructure and

~~agreement types]~~

• A plan curated for: Payers / Insurers* Product list Primary Care Physicians, Specialists,

• Surgeons, Concierge Medicine Groups

Payer coverage is the key driver of revenues for geneType

Coverage from payers in the US will accelerate adoption of geneType Risk Assessment Tests more widely

Budget Impact Model (BIM) demonstrates significant health & economic benefits of implementing the geneType Breast Cancer Risk Assessment Test

11 Active conversations with payer groups in the US

US Payers include:

• Humana – 17 million lives covered

• Aetna – 22.1 million live covered

• Independence Blue Cross – 3 million lives covered

Products

geneType Multi-test

NGS platforms with Germline, Carrier Screening and NIPT

BRCA test & LYNCH Syndrome test

Smaller payers such as employer groups have potential to move quickly

BIM validates the benefits of implementing geneType

24

• Corporates and Insurance market entry assessment in progress and Health Economic Model being completed by ALVA10.

Economic Modeling in the US Payer System[1] The economic benefit to the payers in the US is US$1.4B per annum

==> picture [60 x 32] intentionally omitted <==

==> picture [719 x 305] intentionally omitted <==

----- Start of picture text -----

$73 69% - 74% 6.8%-9.2%
US Payor system overall increase in Supplemental
will save per women getting screening frequency
patient per year screened
14.8% - 8.8% 57% - 67%
Interval Cancers Early-stage cancer
drop detection
----- End of picture text -----

3.6% in annual savings to a payer system in the screening and treatment of breast cancer.

==> picture [53 x 35] intentionally omitted <==

25

1 Corporates and Insurance market entry assessment - Health Economic Model completed by ALVA10 May 2022.

==> picture [60 x 32] intentionally omitted <==

Divisions of Operations

==> picture [90 x 36] intentionally omitted <==

----- Start of picture text -----

Existing divisions
Emerging divisions
----- End of picture text -----

==> picture [147 x 79] intentionally omitted <==

==> picture [52 x 14] intentionally omitted <==

NEW Universal collection test kit to support Multi Test Launch

==> picture [291 x 254] intentionally omitted <==

NEW Universal sample collection kit with TGA, FDA and EU regulatory approval[1]

26

BC = Breast Cancer; CRC = Colorectal Cancer; PC = Prostate Cancer; CVD = Cardiovascular Disease; IHD = Ischemic Heart Disease; Atrial Fibrillation 1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek

DTC - Growth strategy for EasyDNA

PHASE 1 Brand Re-Ignition

PHASE 2

Revenue and Growth Focus

[insert revenue structure and Brand Refresh agreement types] Website Refresh Product list Multi-brand Portfolio Website Development EasyDNA Brand Refresh First-party data collection Test Rationalization Targeted Messaging Improve User experience and engagement

[insert revenue structure and agreement types] Improved Lead Gen New Sales Channels Product list Google Ads Amazon store front Facebook Ads Target B2B customer Content & Email Marketing segments Influencer Marketing & New Markets Testimonials

27

==> picture [204 x 48] intentionally omitted <==

DTC - Growth strategy for EasyDNA

==> picture [510 x 247] intentionally omitted <==

==> picture [159 x 252] intentionally omitted <==

----- Start of picture text -----

28
----- End of picture text -----

==> picture [60 x 32] intentionally omitted <==

Collaborations

Professor Bernard Rosner

==> picture [51 x 59] intentionally omitted <==

==> picture [158 x 41] intentionally omitted <==

Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA – Principal Investigator of the Nurses’ Health Study [insert revenue structure (International expert in Biostatistics and breast cancer epidemiology).and agreement types]

Product list Collaborating on a project to improve the GeneType Breast Cancer Test and to Cross-validate the Ovarian cancer test in the Nurses Health Study

Professor Graham Colditz

==> picture [247 x 63] intentionally omitted <==

Deputy Director, Institute for Public Health. Washington University School of Medicine, St. Louis, Missouri (International expert in Biostatistics and breast cancer epidemiology). [insert revenue structure

Collaborating on a project to validate and agreement types] the GeneType for Breast Cancer Test in Product list African American patients

Professor John Hopper

==> picture [226 x 71] intentionally omitted <==

Professorial Fellow at the Centre for Epidemiology and Biostatistics in the School of Population Global Health, Melbourne University

Collaborating on a project to improv[insert revenue structur e the Genetype for Breast Cancer Test and agreement types] and on a joint project with Prof Emery Product list to develop clinical utility evidence for the GeneType tests

29

==> picture [60 x 32] intentionally omitted <==

Collaborations

Professor Jon Emery

==> picture [99 x 52] intentionally omitted <==

==> picture [138 x 43] intentionally omitted <==

Professor of Primary Care Cancer Research at the University of Melbourne, and the Victorian Comprehensive Cancer Centre[insert revenue structure and agreement types] Collaborating on a joint project with Prof Hopper to develop cl nical utility Product l i st evidence for the GeneType tests

Memorial Sloane Kettering Cancer

==> picture [140 x 82] intentionally omitted <==

Collaborating on a project to investigate modification of risk in BRCApositive patients by polygenic risk scores[insert revenue structure

==> picture [259 x 128] intentionally omitted <==

----- Start of picture text -----

Ohio State
University
----- End of picture text -----

==> picture [123 x 82] intentionally omitted <==

Collaborating on a project to investigate modification of risk in BRCApositive patients by polygenic risk scores[insert revenue structure

30

==> picture [60 x 32] intentionally omitted <==

Snapshot and Achievements last 12 months

GeneType commercialization

EasyDNA integration activities

Reimbursement activation

• ✓ Phase 1 commercial release of the geneType Multi-Risk test in US

• ✓ >90 medical practices on-boarded launching the foundation of geneType Hubs in Australia

• ✓ AffinityDNA

• ✓ Completed 2 Acquisitions – EasyDNA and

• ✓ Presentations by Dr Erika Spaeth at:

• ✓ San Antonio Breast Cancer Symposium,

• ✓ NEW EasyDNA Website ready for launch

• ✓ NEW eCommerce Platform ready launch

• ✓ Launch Carrier Testing and Non-Invasive Prenatal Tests (NIPT) into Europe

• ✓ Partnering in India with stud farms extending paternity infrastructure into the equine industry

• ✓ Launch DNA storage solution in GTG NATA approved facility

• ✓ Independently developed Budget Impact Model (BIM) identifies US$1.4 billion dollars in annual saving by ALVA 10

• ✓ 11 Active payer conversations

• ✓ Progress on US Payer meetings to enable coverage across millions of lives

• ✓ Precision Medicines leaders summit

• ✓ Precision Medicine World Conference

Partnerships

• ✓ Launch with A/Prof Charles Siles providing immediate access to more than 1,000 referring primary care physicians and 15,000 patients annually in Australia

• ✓ Partnerships with Australian Breast Care Centre and Dr Nicole Yap

• ✓ Launch of screening for breast cancer risk with Prof Bruce Mann at Royal Women’s Hospital in Melbourne

Clinical Validity and IP Strategy

• ✓ Published in Journal or Precision Medicine

• ✓ Published in European Journal of Cancer prevention

• ✓ 10 Patents granted

• ✓ 5 new provisional patents filed

• ✓ 4 papers published

• ✓ 3 papers under review

Laboratory Capability

• ✓ Gained NATA and CMS-CLIA accreditation and certification for 6 polygenic risk score tests

• ✓ Successful ARTG notification to TGA for company IVDs for all tests on the multirisk test

31

Thank you

Investor Relations Adrian Mulcahy Market Eye – Automic Group M: +61 438 630 422 E: adrian.mulcahy@automicgroup.com.au

==> picture [51 x 50] intentionally omitted <==

www.linkedin.com/company/genetype-limited www.genetype.com

32

Appendices

==> picture [390 x 142] intentionally omitted <==

==> picture [246 x 446] intentionally omitted <==

33

==> picture [60 x 32] intentionally omitted <==

Corporate Overview

Top 50 share registry breakdown

BNY Mellon Board & Management Other Other, 25% Board & Management , 6%, BNY Mellon, 69%

Dual Listed on the ASX and Nasdaq

==> picture [417 x 257] intentionally omitted <==

----- Start of picture text -----

|||
|---|---|
|Financial Information|
|Share price (AUD) as at 25 October 2022|0.3c|
|ADR price (USD) as at 25 October 2022|$1.20|
|Ord Shares on Issue (M)|9,234|
|ASX 52-week trading (AUD low/high)|0.3/0.8c|
|Nasdaq 52-week trading (USD low/high)|0.95/3.04|
|Market Cap (A$M/US$M)|32.31/18.47|
|Cash at 30 September 2022|A$7.9m|
|Cash at 30 June 2022|A$11.7m|
|Debt (30 June 2022 and 30 September 2022)|nil|

----- End of picture text -----

34

==> picture [60 x 32] intentionally omitted <==

Financial Overview

• Net cash outflow of A$3.4 million in Q1 FY’22 (compared to Q4 FY’22 inflow of: A$197k) as we continue to grow EasyDNA and Affinity DNA brand sales and develop and commercialize our geneType tests

• Cash reserves of A$7.9 million at 30 September 2022 will be directed to:

• Drive the commercialization of geneType products in United States, Europe and Australia

• Develop the direct-to-consumer sales channel through EasyDNA and AffinityDNA

• US Payer model development for geneType for breast cancer;

• General product research and development; and

• For general working capital.

==> picture [454 x 270] intentionally omitted <==

----- Start of picture text -----

A$’000 30-Sep-22 30-Jun-22 Change
Net operating cashflow (3,410) 197 -1831%
Receipts from customers 2,056 2,013 2%
Research and Development and
(2,126) (1,429) 49%
Staff costs
Cash 7,495 11,733 -32%
----- End of picture text -----

1 Based on cashflow projections

35

==> picture [60 x 32] intentionally omitted <==

Board and Management: Sales and Scientific expertise leading GTG

Mr. Peter Rubinstein BEc, LLB Chairman Non – Executive Director

Dr. Lindsay Wakefield MBBS Non – Executive Director

==> picture [73 x 78] intentionally omitted <==

Mr Nick Burrows B.Comm, FAICD, FCA, FGIA, FTIA, F Fin Non – Executive Director

Simon Morriss GAICD Chief Executive Officer

Dr. Jerzy “George” Muchnicki MBBS Non-Executive Director

==> picture [78 x 78] intentionally omitted <==

Erika Spaeth PhD Director of Clinical & Scientific Affairs

Richard Allman BSc, PhD Scientific Advisor

==> picture [121 x 143] intentionally omitted <==

Tony Di Pietro B. Comm, CA, AGIA, MAICD CFO & Company Secretary

==> picture [77 x 78] intentionally omitted <==

Carl Stubbings Chief Commercial Officer

36

==> picture [60 x 32] intentionally omitted <==

Strong Scientific Leadership: Advisory Board

Professor Jon Emery

MBBCh MA DPhil FRACGP MRCGP Research & Education Lead, Primary Care Integration, Victorian Comprehensive Cancer Centre Herman Chair of Primary Care Cancer Research, University of Melbourne

Professor Finlay Macrae AO

MBBS, MD, FRACP, FRCP, AGAF MWGO is Principal Fellow and Professor, Department of Medicine, University of Melbourne, and Head of Colorectal Medicine and Genetics, The Royal Melbourne Hospital

==> picture [70 x 70] intentionally omitted <==

Ora K. Gordon, M.D.

MD, MS, FACMG

Regional Medical Director, Center for Clinical Genetics & Genomics. Clinical Director, PSJH Population Health Genomics Program. Chair, Integrated Network Cancer Program, Professor of Genetics, St John Cancer Institute

==> picture [75 x 72] intentionally omitted <==

A.Prof Ron Dick

MBBS, FRACP, FCSANZ, Chairman of Cardiovascular Institute at Epworth Healthcare, an Honorary Cardiologist at the Alfred Hospital and Bendigo Healthcare Group.

Completed his MBBS in 1979 and became a Fellow of the Australian College of Physicians in 1986. His interventional cardiology fellowship was from the University of Michigan Medical Centre USA.

37

==> picture [60 x 32] intentionally omitted <==

Our Intellectual Property

4 Patents granted in the US

9 Patent families pending

• Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection

• Patent No: US 11,072,830, Methods for breast cancer risk assessment

• Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer

• Patent No: US 10,920,279, Methods for assessing risk of developing breast cancer

2 Patents granted in PRC (China & HK)

• Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment

• Breast cancer risk assessment

• Methods for assessing risk of developing prostate cancer

• Methods for assessing risk of developing ovarian cancer

• Methods of assessing risk of developing a severe response to Coronavirus infection

• Methods of assessing risk of developing a disease

• Methods for assessing risk of developing breast cancer

• Improved methods for assessing risk of developing breast cancer

  • Methods of assessing risk of developing breast cancer

• Methods for assessing risk of developing colorectal cancer

• Patent No. 201580063966.2 Methods for assessing risk of developing breast cancer

38

• Patents granted are specific to the GeneType portfolio of products

==> picture [60 x 32] intentionally omitted <==

Defined Terms

Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease.

Polygenic risk score - a number associated with one’s disease risk based on the aggregated effects of individual risk variants through a multiplicative algorithm.

Variant - Single Nucleotide polymorphism (SNP), an alteration in DNA that may be a common or rare event.

Genomic - pertaining to function of genetics from structure to relationship between genetic events.

Genetic - pertaining to a gene.

GWAS - genome-wide association studies are large population level studies which enable scientists to identify genes and genetic markers involved in human disease. This method searches the genome for SNPs that occur more frequently in people with a particular disease than in people without the disease. Each study can look at hundreds or many thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint genetic variations that may contribute to a person’s risk of developing a certain disease.

SNP - Single nucleotide polymorphisms, frequently called SNPs (pronounced “snips”), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.

• Serious Disease Risk (SDR) Risk associated with acquiring COVID-19 and requiring hospitalisation withs its associated morbidities and mortalities.

Germline Testing – Germline testing is done on cells that do not have cancer. It is done to see if a person has a gene mutation that is known to increase the risk of developing cancers and other health problems. This test uses cells (such as blood or skin cells) that do not have any cancer cells. Germline mutations can sometimes be passed down from parents.

Clinical Laboratory Improvement Amendments (CLIA) - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing

National Association of Testing Authorities (NATA) - the authority responsible for the accreditation of laboratories, inspection bodies, calibration services, producers of certified reference materials and proficiency testing scheme providers throughout Australia. It is also Australia's compliance monitoring authority for the OECD Principles of GLP. NATA provides independent assurance of technical competence through a proven network of best practice industry experts for customers who require confidence in the delivery of their products and services.

Next Generation Sequencing ( NGS) – Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionised the study of genomics and molecular biology.

Laboratory Developed Tests (LDT) – A type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory.

Consumer Initiated Tests (CIT) - laboratory testing that is initiated by the consumer without a physician order but reviewed and communicated back to the consumer via a physician.

Direct to Consumer (DTC) – laboratory testing that is initiated by the consumer without a physician order. The results are reported back directly to the consumer.

Health Care Professionals (HCP) – physician, GP, or specialist authorized to receive the patient results

39